← Outlook Therapeutics, Inc. (OTLK) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Outlook Therapeutics, Inc. (OTLK)
Biological Products, (No Diagnostic Substances) · market cap $166M · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-06-13 (est.)
PDUFA
Pipeline
1
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Outlook Therapeutics (OTLK) is a micro-cap clinical-stage biotech with 23 employees pursuing FDA approval for bevacizumab (ophthalmic formulation) and ranibizumab in wet age-related macular degeneration, both in Phase 3. With only $7.7M cash and an estimated one-month runway, the company faces an acute near-term financing crisis that overshadows any clinical narrative.
The catalyst path
- 2027-06-13 (est.)PDUFAimp 8/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ranibizumab | Phase 3 | Age-related Macular Degeneration |
Price & technical context
3-month
-61.2%
6-month
+177.0%
12-month
-46.2%
52-wk range
$0.20–$2.47
vs 50-day MA
-28.4%
vs 200-day MA
-24.8%
Realized vol
170.1%
Max drawdown
-97.0%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for OTLK (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.